ReviewAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2020
Management of chronic obstructive pulmonary disease: A review focusing on exacerbations.
Review in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05835492 (A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD), which is not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Differentiating the start of an exacerbation from day-to-day variation in people with COPD: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Efficacy of Jinshui Liujun decoction on chronic obstructive pulmonary disease patients: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.Respiratory research · 2022Pooled it
- Role of new digital technologies and telemedicine in pulmonary rehabilitation : Smart devices in the treatment of chronic respiratory diseases.Wiener klinische Wochenschrift · 2021Pooled it
- Trial
- Carbocisteine Reduces Airway Mucus Obstruction and Alters Inflammatory Cell Populations in a Model of Muco-Obstructive Lung Disease.Immunology and cell biology · 2026Article
- Who Enrolls After Referral to Virtual Pulmonary Rehabilitation? A Descriptive Comparison.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Discharge Practices After Hospitalization for COPD Exacerbations: A Physician Survey and SWOT Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Symptomatic Changes Associated With a Pharmacist-Led COPD Program.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Scalable Identification of Clinically Relevant Chronic Obstructive Pulmonary Disease Documents in Large-Scale Electronic Health Record Datasets With a Lightweight Natural Language Processing Model: Retrospective Cohort Study.JMIR medical informatics · 2026Article
- Recruitment for a digitally based follow-up program for people with chronic obstructive pulmonary disease: a pilot cluster randomized controlled trial.Pilot and feasibility studies · 2026Article
- Chronic Obstructive Pulmonary Disease and Asthma Among Workers and Residents of Navanakorn Industrial Zone, Thailand.Medical sciences (Basel, Switzerland) · 2026Article
- Article
- Medical gases and long-term oxygen therapy: reducing the chronic obstructive pulmonary disease burden in aging populations in Sub-Saharan Africa.Medical gas research · 2026Review
- Estimation of carbon emissions from inhaled respiratory medicines in Ireland: a cross-sectional study from a national pharmacy claims database from 2020 to 2022.International journal of clinical pharmacy · 2026Article
- Microplastics as environmental modifiers of lung disease.EMBO molecular medicine · 2026Review
- Outstanding Contributions to Aerosol Pulmonary Drug Delivery.Kona : powder science and technology in Japan · 2026Article
- Intention to Use Digital Health Among COPD Patients in Europe: A Cluster Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.Frontiers in pharmacology · 2026Article
- Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.Frontiers in immunology · 2026Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality in the United States. Exacerbations- acute worsening of COPD symptoms-can be mild to severe in nature. Increased healthcare resource use is common among patients with frequent exacerbations, and exacerbations are a major cause of the high 30-day hospital readmission rates associated with COPD. SUMMARY: This review provides a concise overview of the literature regarding the impact of COPD exacerbations on both the patient and the healthcare system, the recommendations for pharmacologic management of COPD, and the strategies employed to improve patient care and reduce hospitalizations and readmissions. COPD exacerbations significantly impact patients' health-related quality of life and disease progression; healthcare costs associated with severe exacerbation-related hospitalization range from $7,000 to $39,200. Timely and appropriate maintenance pharmacotherapy, particularly dual bronchodilators for maximizing bronchodilation, can significantly reduce exacerbations in patients with COPD. Additionally, multidisciplinary disease-management programs include pulmonary rehabilitation, follow-up appointments, aftercare, inhaler training, and patient education that can reduce hospitalizations and readmissions for patients with COPD.
conclusionMaximizing bronchodilation by the appropriate use of maintenance therapy, together with multidisciplinary disease-management and patient education programs, offers opportunities to reduce exacerbations, hospitalizations, and readmissions for patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.